$2.8M in federal grants to JAX scientists to target triple-negative breast cancers

March 03, 2017

Two grants from the U.S. Department of Defense totaling $2.8 million will support Jackson Laboratory (JAX) research in one of the most deadly forms of breast cancer, known as triple-negative breast cancer (TNBC).

About 3 million American women are living with breast cancer. Advances in understanding the biological and genetic profiles of individual cancers have contributed to better screening and more targeted treatments, leading to a steady rise in the overall five-year survival rate following a breast cancer diagnosis to about 89 percent.

However, triple-negative breast cancer (TNBC), by definition, eludes three of the most effective therapies that target cancer-driving molecules: estrogen receptors, progesterone receptors, or large amounts of HER2/neu protein. TNBC accounts for up to 20 percent of all breast cancers and is associated with poor outcomes for patients, because of this resistance and its capacity for aggressive growth and high recurrence.

A grant of $1,393,246 to JAX President and CEO Edison Liu, M.D., will fund further exploration of his discovery of a characteristic of TNBC tumors, with the goal of developing better diagnostics and more targeted treatments for patients with TNBC. JAX Professor Karolina Palucka, M.D., Ph.D., was awarded $1,386,446 to advance her investigations into harnessing the immune system to combat TNBC.

"TNBC tumors have complex and massive changes to their entire DNA makeup, also known as the cancer genome," says Liu. "By analogy, where a single change might be seen as a misplaced letter in a gene, many cancer genes in TNBC are misspelled, repeated wholesale or deleted in many different places. Because it is much more difficult to read so many changes at once, it is also harder to identify those that are important for TNBC growth and sensitivity to treatment."

Last year Liu discovered that TNBC tumors and certain other deadly cancers of women (including serous ovarian cancer and endometrial carcinomas) share a genomic configuration described as a tandem duplicator phenotype (TDP). Moreover, they showed that tumors with this configuration respond to a specific chemotherapy, cisplatin.

Since that discovery, the Liu lab has found that not all TDP TNBC tumors are the same. "We now have strong preliminary data identifying subtypes of genetically different TDP TNBCs," Liu says, "and for each subtype we have found genes that likely drive these genetic differences and for which specific therapies are already FDA-approved or in development."

With the new grant, and in collaboration with Ralph Scully, MBBS, Ph.D., of Beth Israel Deaconess Medical Center, Liu and his lab will use advanced computational methods to develop a more precise approach for classifying TNBC tumors, a better understanding of the formation of TDP subtypes, and novel treatment regimens tailored to specific TDPs that will be ready for testing in a clinical setting.

"Our research shows that while TDP TNBC is highly complex," Liu says, "we have the tools to unpack this complexity in a way that creates unprecedented opportunities for better classifying, treating and curing TNBC cancers."

Almost 90 percent of deaths due to breast cancer are attributed to metastatic disease (cancer cells spreading to distant organs), and treatments used to shrink or slow metastatic tumors provide only temporary relief: There is no cure for metastatic breast cancer. While some TNBC patients respond initially to conventional therapies, nearly half will experience recurrence and metastasis within two to three years.

Thus, says, Palucka, understanding the underlying mechanisms that control metastasis is of critical importance for the discovery and development of new, targeted treatments and for the increased survival of TNBC cancer patients.

"One promising entry point for understanding progression to metastasis--and determining how to prevent it--is to focus on the interplay between the immune system and cancer cells," she says.

Palucka has developed a special mouse model that replicates the human immune system to better understand its effect on the tumor microenvironment, cancer cell longevity and metastatic spread to other organs.

In preliminary results, she has discovered that the presence of human cytokines (proteins that stimulate immune cells) induces cancer cells to spread to distant organs; in fact, metastasis did not occur in the mice lacking human cytokines. "This distinction will allow us to precisely define immune cells or signals that drive cancer cells to spread--signals that could represent promising therapeutic targets for intervention," Palucka says.

And, she notes, the utility of this model extends beyond TNBC to other metastatic cancers as well. "The potential benefit of this work could be the identification of new treatment targets for limiting metastasis in at-risk patients, possibly improving the ability to cure patients with this devastating disease."
The Jackson Laboratory is an independent, nonprofit biomedical research institution based in Bar Harbor, Maine, with a National Cancer Institute-designated Cancer Center, a facility in Sacramento, Calif., and a genomic medicine institute in Farmington, Conn. It employs 1,900 staff, and its mission is to discover precise genomic solutions for disease and empower the global biomedical community in the shared quest to improve human health.

Jackson Laboratory

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.